Findings of Australian trial of CSL’s Pandemic (H1N1) 2009

Findings of Australian trial of CSL’s Pandemic (H1N1) 2009

Melbourne, Australia — 21/12/2009

CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine’ flu vaccine. Results of the trial demonstrate a robust immune response after a single dose in children as young as 6 months of age, which is further enhanced by the administration of a second dose given 3 weeks later. 

The clinical study included 370 healthy infants and children aged 6 months to 9 years located in Perth, Adelaide, Melbourne, Sydney and Brisbane. Participants were divided into two groups, and given either a 15 mcg or a 30 mcg dose of the vaccine. A second dose was given to each group three weeks later. Blood samples to test protective antibody levels were taken at baseline, and following each dose.

Download the full release:
CSL Australian Trial of Paediatric Swine Flu (0.05MB)


Media Contacts:

Dr Rachel David
Director of Public Affairs
CSL Limited
Phone: +61 401 775 779
Email: rachel.david@csl.com.au
© 2016 CSL Limited